SAN DIEGO--(BUSINESS WIRE)--Kelaroo, Inc. announced today that it has received a strategic equity investment from, and expanded its contract research with, Amylin Pharmaceuticals, Inc. Amylin’s PHINDER system for peptide hormone identification and optimization was developed using Kelaroo’s proprietary SeqR(TM) technology, an innovative sequence-profiling approach that combines machine learning methods and high performance sequence analysis tailored for genome-scale data mining and sequence optimization.
